ArticleScientific reports2025
Revealing inhibitory activity of luteolin from Vietnamese Jatropha Podagrica Hook against Staphylococcus aureus by integrating in vitro and in silico approaches.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Molecular basis and therapeutic potential of sortase A inhibitors as new antibiotics against MDR pathogens.Open biology · 2026Review
- Isolation, Bromination, and Antimicrobial Activity of 3-Ethyl-4-hydroxy-6-methyl-Antibiotics (Basel, Switzerland) · 2026Article
- Cytotoxic and apoptotic effects of kaempferol 3-O-rhamnoside from Schima wallichii in HepG2 cells.Scientific reports · 2026Article
- Chrysin and Luteolin from Moroccan Propolis to Prevent Aggressive Periodontitis Caused byPharmaceuticals (Basel, Switzerland) · 2026Article
- Bioassay-guided isolation and structural characterization of antimicrobial phytoconstituents fromFrontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA) are increasingly prevalent pathogens associated with multidrug-resistant infections in both hospital and community. In this study, we evaluated the antibacterial activity of Jatropha podagrica Hook. extracts collected from Vietnam against S. aureus and MRSA. Among various plant parts, the root extract exhibited the most potent activity, with an MBC/MIC ratio of 2.0, indicating bactericidal properties. To elucidate the mechanism of action and identify potential bioactive constituents, a virtual screening of 43 phytochemicals from J. podagrica was performed against sortase A (SrtA), a key virulence factor of S. aureus, using molecular docking. Among them, luteolin demonstrated the highest binding affinity (ΔG = - 9.3 kcal/mol) and formed multiple stable interactions with catalytically important residues such as His120, Cys184, and Arg197. Further molecular dynamics simulations over 100 ns confirmed the structural stability of the luteolin-SrtA complex, with minimal RMSD fluctuation and sustained hydrogen bonding throughout the simulation. Protein-ligand contact analysis revealed consistent interactions involving hydrogen bonds, hydrophobic contacts, and π-alkyl interactions, supporting a well-anchored and dynamically stable binding pose. In addition, in vitro experiments results showed that luteolin inhibited the growth of S. aureus and MRSA at a MIC of 31.25 µg/mL and showed a bacteriostatic profile with an MBC/MIC ratio > 4.0. This study provides the first comprehensive report on the antibacterial potential of J. podagrica from Vietnam, and highlights luteolin as a promising lead compound targeting bacterial virulence through SrtA inhibition, supporting its further development as an adjunctive or alternative anti-MRSA therapeutic agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.